drugset / Trial / NCT00109863
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
Phase 2
Completed
14 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.
Timeline
- Start
- 2005-05
- Primary completion
- 2007-07
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hu14.18-IL2 | Monoclonal antibody | 6 mg/m2 | Intravenous |